HIV / AIDS

Judith Feinberg, MD, FIDSA, describes surprising outcomes in many COVID-19 cases among people living with HIV.

Evolving research has led the infectious diseases community to redefine its definition of cure.

Conversations about PrEP with a clinician are the least common among adolescents with the greatest risk for HIV.

Sky-high HIV drugs costs are a significant barrier to adherence and our goal of eradicating the virus.

HOPS offers an abundance of data on the evolution of HIV that can guide the management of the disease.

A hospital case series of patients with both COVID-19 and HIV describes recovery, but highlights the need to refine treatment.

Despite significant levels of inflammation, sickle cell patients run a lower risk of HIV transmission than patients with other anemias.

Tuberculosis is a threat to people living with HIV and finding preventive therapies that don’t cause interactions with antiretrovirals is a priority.

HIV training pathways in residency have added 90 HIV physicians to the workforce since 2006.

Funded jurisdictions scramble to meet daunting deadlines yet maintain optimism that the new federal initiative can end flat funding and catalyze progress.

When drug resistance means ART options are exhausted, HIV patients need newer choices. A new study shows that novel prodrug fostemsavir is an effective alternative.

A new analysis in the CDC’s MMWR points to success in ART initiation and viral suppression among active duty members of the US armed forces.

With advancements in antiretroviral therapy, people with HIV are now living longer and developing age-related chronic conditions.

Rural counties are less likely to have an experienced HIV clinician, despite increasing HIV incidence.

Ian Frank, MD, explains the different conceptual understandings of what an HIV cure might entail.

A poster presented at CROI 2020 examined rates of TB screening among people living with HIV in PEPFAR supported countries.

Ian Frank, MD, gives an overview of different HIV vaccine efforts in recent years and on the horizon.

Trainees in a new study using HIV-ASSIST were significantly more likely to choose appropriate ART regimens compared to those using guidelines alone.

From 2013 to 2018, new HCV cases fell 68% among men living with HIV in 2 UK cities, London and Brighton.